// App-Quantinova.ai

54 : Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Researchers

Presenter

  • Srdan Verstovsek

Principal Investigators

  • Ewa Lech-Maranda

  • Tomasz Sacha

  • Viviane Dubruille

  • Stephen T. Oh

  • Doroteya Todorieva-Todorova

  • Francesco Passamonti

  • Blanca Xicoy

  • Bjrn Andrasson

  • Daniel El Fassi

  • Claire Harrison

  • Donal P. McLornan

  • Mary Frances Frances McMullin

  • Christof Scheid

  • MArianne Tang Severinsen

  • Mark M Kowalski

  • Gregg Smith

  • Ruben Mesa

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Hematológiai Osztály, Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa,

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Pediatric Hematology, Nantes University Hospital, Nantes, France

  • Washington University School of Medicine, St. Louis, MO

  • Hematology Division, Medical University, Pleven, BGR

  • Hematology, Department of Medicine and Surgery, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy

  • Hematology section, Uddevalla Sjukhus, NU Hospital Group, Uddevalla, Sweden

  • Herlev University Hospital, Copenhagen, KøBenhavn S, DNK

  • Department of Haematology, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom

  • Systems Cancer Immunology, Comprehensive Cancer Centre, Kings's College Hospital, London, United Kingdom

  • Queen's University Belfast, Belfast, United Kingdom

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Sierra Oncology Inc., Vancouver, BC, Canada

  • Sierra Oncology Inc., Vancouver, BC, Canada

  • UT Health San Antonio Cancer Center, San Antonio, TX

Locations

  • United States

  • Hungary

  • Poland

  • France

  • Italy

  • Spain

  • Sweden

  • United Kingdom

  • Germany

  • Denmark

  • Canada

Companies

  • Sierra Oncology, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Janus kinase

Drug/Treatment

  • Momelotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved